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STUDY PROTOCOL Open Access
TREatment of ATopic eczema (TREAT)
Registry Taskforce: protocol for an
international Delphi exercise to identify a
core set of domains and domain items for
national atopic eczema registries
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Abstract
Background: Patients with moderate-to-severe atopic eczema (AE) often require photo- or systemic immunomodulatory
therapies to induce disease remission and maintain long-term control. The current evidence to guide clinical
management is small, despite the frequent and often off-label use of these treatments. Registries of patients on photo-
and systemic immunomodulatory therapies could fill this gap, and the collection of a core set concerning these therapies
in AE will allow direct comparisons across registries as well as data sharing and pooling.
Using an eDelphi approach, the international TREatment of ATopic eczema (TREAT) Registry Taskforce aims to seek
consensus between key stakeholders internationally on a core set of domains and domain items for AE patient registries
with a research focus that collect data of children and adults on photo- and systemic immunomodulatory therapies.
Methods/design: Participants from six stakeholder groups will be invited: doctors, nurses, non-clinical researchers,
patients, as well as industry and regulatory body representatives. The eDelphi will comprise three sequential online
rounds, requesting participants to rate the importance of each proposed domain and domain items. Participants will be
able to add domains and domain items to the proposed list in round 1. A final consensus meeting will be held with
representatives of each stakeholder group.
Discussion: Identifying a uniform core set of domains and domain items to be captured by AE patient registries will
increase the utility of individual registries, and provide greater insight into the effectiveness, safety and cost-effectiveness
of photo- and systemic immunomodulatory therapies to guide clinical management across dermatology centres and
country borders.
Trial registration: Not applicable. This eDelphi study was registered in the Core Outcome Measures for Effectiveness
Trials (COMET) database.
Keywords: Atopic eczema, Atopic dermatitis, Delphi, Consensus methods, Patient registries, Disease registries, Core set,
Daily practice data, Immunomodulatory therapies, Interoperability
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Background
Atopic eczema (AE) (synonymously ‘atopic dermatitis’) is
among the most common chronic inflammatory disor-
ders, with a lifetime prevalence of 15–30% in children and
2–10% in adults [1] and is known to give a high burden of
disease to patients, their families and society [2]. Whilst
most patients with AE can be treated effectively with
emollients and topical anti-inflammatory agents, a signifi-
cant number will require photo- or systemic immuno-
modulatory therapies to induce disease remission and
maintain long-term control [3]. Ciclosporin is currently
the only systemic treatment approved by the European
Medicines Agency (EMA) as a treatment for severe AE
[4]. Alternative, but off-label, systemic immunomodula-
tory therapies include methotrexate, azathioprine, myco-
phenolic acid (mycophenolate mofetil or mycophenolate
sodium), systemic glucocorticosteroids, and intravenous
immunoglobulin. Novel agents are currently tested in clin-
ical trials (e.g. dupilumab, lebrikizumab, apremilast, uste-
kinumab, and CRTH2 antagonist (chemoattractant
receptor-homologous molecule expressed on Th2 cells)).
The current evidence to guide clinical management
for moderate-to-severe AE originates from a small body
of randomised controlled trials (RCTs) [5] and observa-
tional studies [6–8]. There are no long-term, compara-
tive and real-life data on the effectiveness and safety of
these treatments in children or adults from large-scale,
multicentre cohort studies. Several scientific guidelines
and a systematic review highlight these gaps [5, 9, 10]
and lament the resulting lack of clear management guid-
ance to inform clinical practice.
Nevertheless, as shown in a recent survey among over
700 dermatologists and paediatricians from eight Euro-
pean countries, these immunomodulatory treatments are
frequently prescribed as off-label medicines in children
[11]. It is likely that these treatments are used more fre-
quently in adults, but no research has yet been performed.
The establishment of national AE patient registries with
a research focus that use the same methodology would
not only partially fill the gaps in the current evidence, but
could also operate as a research platform to inform the
design of future RCTs and basic research and serve as an
example for other initiatives. Such a platform will allow
the collection of prospective daily practice data on effect-
iveness, safety, cost-effectiveness, subgroup characteristics,
quality of care and personalised medicine. Our research
group, the TREatment of ATopic eczema (TREAT) Regis-
try Taskforce, is currently developing an interoperable pa-
tient registry platform based on best-practice guidelines
for this purpose [12].
Experience has shown that disease registries that were
set up without an a priori agreed core set are likely to
yield disparate datasets, hampering direct comparisons
of results and data pooling [13]. To overcome this
problem, an internationally agreed core set for AE pa-
tient registries is required. The European Commission
funded PAtient REgistries iNiTiative Joint Action (PAR-
ENT JA) has developed methodological guidelines for
the development of patient registries in cross-border set-
tings [12] to reduce heterogeneity, enhance direct com-
parability of individual country data and improve data
pooling between countries.
In alignment with the PARENT guidance, the objective
of this eDelphi study is to reach international consensus
between different stakeholders on a core set of domains
and domain items (what to measure), for existing and fu-
ture atopic eczema patient registries with a research focus,
that collect data of children and adults on photo- and sys-
temic immunomodulatory therapies. This protocol out-
lines the methodology.
Methods/design
This study will be conducted following the recommended
checklist proposed by Sinha et al. [14], of items that should
be reported in studies using the Delphi technique [15]. De-
tails of our study have been included in the Core Outcome
Measures for Effectiveness Trials (COMET) database and
are available at www.comet-initiative.org/studies/details/
825?result=true. The Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) checklist can be
found in Additional File 1.
Study design
To investigate domains and domain items of import-
ance, an online Delphi exercise (further referred to as
‘eDelphi’) in combination with a consensus meeting will
be conducted (Fig. 1).
The eDelphi approach comprises sequential question-
naires answered anonymously by key stakeholder groups.
The answers are anonymised to avoid participants being
influenced by the opinions of other group members, and
thus minimise bias. After each questionnaire round, a
summary of the responses is fed back to the group. Indi-
vidual participants may then decide to keep their original
answers or to change their opinion in the next round.
Gradually, a consensus evolves as in general the range of
answers decreases and the group converges towards a
consensus opinion over the course of several rounds [14].
After the eDelphi exercise, a consensus meeting will be
organised with representatives from each stakeholder
group to resolve potentially remaining disagreements and
to agree on a core set of domains and domain items.
Participants
Representatives from six key stakeholder groups [16]
will be identified and invited to participate in the
consensus study:
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1. Health care professionals – doctors who care for
patients with moderate-to-severe AE, including
doctors who are involved in AE clinical research
2. Health care professionals – nurses who care for
patients with moderate-to-severe AE
3. Non-clinical researchers with a specialist and active
research interest in AE, e.g. methodologists,
epidemiologists, health economists
4. Patients (adult patients and carers of children or
adults with AE)
5. Industry representatives from pharmaceutical
companies involved in the development of systemic
immunomodulatory drugs for AE
6. Regulatory body representatives from the EMA, US
Food and Drug Administration (FDA) and national
regulatory bodies such as the UK National Institute
for Health and Care Excellence (NICE)
Panel size and recruitment
Currently, there are no official recommendations for the
number of participants to include in an eDelphi study
[17]. Because of the six stakeholder groups and their
possible diversity of opinions, we will recruit as many
representatives for each stakeholder group as possible
and from as many counties as possible.
To identify health care professionals and non-clinical re-
searchers to participate in the eDelphi, we will approach
relevant international societies registered with the Inter-
national League of Dermatological Societies (ILDS) and
other relevant special interest groups (e.g. the Inter-
national Eczema Council) (Table 1). Societies will be asked
to send out an email with the link to our eDelphi, and
their members can register if they want to participate.
Members who want to participate will also be asked to
cascade the link to other relevant experts in the field. Pa-
tient representatives will be recruited from national ec-
zema support groups (Table 2), again by email invitation.
By sending the survey invitation to societies from different
parts of the world, we aim to include patients of different
skin types and cultures. Industry representatives will be in-
vited from pharmaceutical companies that have developed
systemic drugs for AE or are known to have such medica-
tions in development. Finally, representatives from regula-
tory bodies (i.e. EMA, FDA, national regulatory bodies)
will be identified through personal contacts from Europe
and the United States. The invitation letter containing an
embedded link to the eDelphi questionnaire can be found
in Additional file 2.
Members of the TREAT Research Group will partici-
pate in the eDelphi exercise as well as in the final con-
sensus meeting.
eDelphi questionnaire
The eDelphi questionnaire has been developed using a
comprehensive list of domains (i.e. high-level data, e.g.
physical examination) and domain items (i.e. more granu-
lar data, e.g. blood pressure) identified by the TREAT Re-
search Group through panel discussions and by literature
review. For the ‘physician- and patient-reported’ domain
and domain items a direct reference was made to guid-
ance from the Harmonising Outcome Measures for Ec-
zema (HOME) initiative (homeforeczema.org). After
obtaining an initial list of domains and items, the mem-
bers of the TREAT Research Group were again asked to
Fig. 1 The TREatment of ATopic eczema (TREAT) Delphi exercise
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Table 1 List of (inter)national societies to be invited
Category Name of society
International dermatology
societies
African Association for Dermatology
African Dermatovenereology Association
Asian Academy of Dermatology and
Venereology
Asian Dermatological Association
Association of French Speaking
Dermatologists
Caribbean Dermatology Association
European Academy of Dermatology and
Venereology (EADV)
European Dermatology Forum (EDF)
European Society for Dermatological
Research (ESDR)
European Society for Photodermatology
(ESPD)
Gulf Cooperation Council League of
Dermatologists
Ibero Latin American College of
Dermatology (CILAD)
International Forum for the Study of Itch
International Society of Dermatology
Pacific Dermatologic Association
Palestinian Society of Dermatology and
Venereology (PSDV)
Pan Arab League of Dermatology
South Asian Regional Association of
Dermatologists, Venereologists and
Leprologists (SARAD)
Women’s Dermatologic Society
International dermatology
special interest societies
European Dermato-Epidemiology Net-
work (EDEN)
European Taskforce on Atopic Dermatitis
(ETFAD)
Harmonising Outcome Measures for
Eczema (HOME)
International Eczema Council (IEC)
International Society of Atopic Dermatitis
(ISAD)
European Registry of Psoriasis (PSONET)
Dermatology nursing
societies
Australian Dermatology Nurses’
Association (ADNA)
British Dermatological Nursing Group
(BDNG)
Dermatology Nurses Association (DNA)
International Skin Care Nursing Group
(ISNG)
Paediatric dermatology
societies
British Society of Paediatric Dermatology
(BSPD)
Deutsche Gesellschaft für Kinder- und
Jugendmedizin e.V. (DGKJ)
Table 1 List of (inter)national societies to be invited (Continued)
European Society of Paediatric
Dermatology (ESPD)
French Society for Pediatric Dermatology
International Society of Paediatric
Dermatology (ISPD)
Japanese Society of Pediatric
Dermatology
Latin American Pediatric Dermatology
Society
Nederlands-Belgische vereniging voor
Kinderdermatologie (Kinderhuid)
Society for Pediatric Dermatology (SPD)
National dermatology
societies
Algerian Society of Dermatology
American Academy of Dermatology
(AAD)
American Dermatological Association
(ADA)
Argentine Society of Dermatology (SAD)
Asociacion Colombiana de Dermatoloiga
y Cirugia Dermatologica (AsoColDerma)
Asociacion Ecuatoriana de Dermatologia
y Ciencias Afines (AEDCA)
Asociacion Guatemalteca De
Dermatologia
Association of Dermato-Venerologists of
Latvia (BADV)
Association of Italian Clinical
Dermatologists (AIDA)
Association of the Italian Women
Dermatologists (DDI)
Association of Professors of Dermatology
USA (APD)
Australasian College of Dermatologists
(ACD)
Austrian Society for Dermatology and
Venereology (OEGDV)
Belarusian Society of
Dermatovenereologists and
Cosmetologists
Belgian Society of Dermatology and
Venereology
Brazilian Society of Dermatology (SBD)
British Association of Dermatologists
(BAD)
Bulgarian Dermatological Society
Canadian Dermatology Association (CDA)
Chilean Society of Dermatology and
Venereology
Chinese Society of Dermatology (CSD)
Croatian Dermatovenerological Society of
the Croatian
Cyprus Society of Dermatology and
Venereology
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Table 1 List of (inter)national societies to be invited (Continued)
Czech Academy of Dermatovenereology
(CADV)
Czech Dermatovenereology Society
(CDS)
Dansk Dermatologisk Selskab (DDS)
Dermatologic Society of Iceland
Dermatological Society of Malaysia (PDM)
Dermatological Society of Mauritius
Dermato-venereology Senegalese Society
Dermatological Society of Singapore
(DSS)
Dermatological Society of South Africa
(DSSA)
Dermatological Society of Thailand (DST)
Dermatovenereology Association of
Turkey
Dutch Society of Dermatology and
Venereology (NVDV)
Eczema Clinical Network New Zealand
Egyptian Society of Aesthetic
Dermatology
Finnish Society of Dermatology (Suomen
Ihotautilääkäriyhdistys) (SILY)
French Society of Dermatology (SFD)
Georgian Association of Dermatology
and Venereology (GADV)
German Dermatological Society (DDG)
Hellenic Society of Dermatology and
Venereology (EDAE)
Honduran Society of Dermatology and
Dermatologic Surgery
Hong Kong College of Dermatologists
(HKCD)
Hong Kong Society of Dermatology and
Venereology (HKSDV)
Hungarian Dermatological Society (MDT)
Indian Association of Dermatologists,
Venereologists and Leprologists (IADVL)
Indonesian Society of Dermatology and
Venereology (PERDOSKI)
Iranian Society of Dermatology
Irish Association of Dermatologist
Israel Society of Dermatology and
Venereology (ISDV)
Italian Association of Hospital
Dermatologists (ADOI)
Italian Society of Allergological,
Occupational and Environmental
Dermatology (SIDAPA)
Italian Society of Dermatology
(SIDeMaST)
Table 1 List of (inter)national societies to be invited (Continued)
Ivoirienne Society of Dermatology and
Venereology (SIDV)
Japanese Dermatological Association
(JDA)
Japanese Organization of Clinical
Dermatologists (JOCD)
Japanese Society for Investigative
Dermatology
Jordanian Society for Dermatology and
Venereology (JSDV)
Korean Dermatological Association (KDA)
Kuwait Society of Dermatologists (KSD)
Lebanese Dermatological Society
Libyan Society of Dermatology and
Venereology
Maltese Association of Dermatology and
Venereology
Mexican Academy of Dermatology (AMD)
Mexican Society of Dermatology
(SMDAC)
Mongolian Dermatological Society
Moroccan Society of Dermatology (SMD)
New Zealand Dermatological Society Inc.
(NZDS)
Nicaraguan Association of Dermatology
Nigerian Association of Dermatologists
(NAD)
Norwegian Society of Dermatology and
Venereology (NSDV)
Oman Dermatology Society (ODS)
Pakistan Association of Dermatologists
(PAD)
Paraguayan Society of Dermatology
Peruvian Society of Dermatology (SPD)
Philippine Academy of Clinical and
Cosmetic Dermatology (PACCD)
Philippine Dermatological Society (PDS)
Polish Dermatological Society (PTD)
Portuguese Society of Dermatology and
Venereology (SPDV)
Romanian Society of Dermatology (SRD)
Russian Society of Dermatovenerologists
and Cosmetologists (RODV)
Salvadorian Association of Dermatology
Saudi Society of Dermatology and
Dermatologic Surgery (SSDDS)
Serbian Association of
Dermatovenereologists
Slovak Dermatovenereological Society
(SDVS)
Sociedad Ecuatoriana de Dermatologia
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review and to add any additional domains and items that
they thought should be included. This led to a proposed
list of core domains and domain items for the eDelphi
questionnaire (Table 3).
Some domains and domain items identified were
found obvious by the TREAT Research Group through
panel discussions, e.g. age and gender, and will, there-
fore, not be included in the eDelphi but listed separately
(Table 4). This list will be sent to all potential eDelphi
participants, attached to the invitation email, and will be
made available on the introduction page of the first
round of the eDelphi survey. Participants will be asked
to confirm whether they feel that any of these domains
or domain items should not be automatically included
but rather should be included in the eDelphi. In this
way, they have the option to add these domains or do-
main items in round 1.
In addition, patients with AE have critically reviewed
the protocol, questionnaire and invitation email con-
cerning content and language to allow patient represen-
tatives to take part in the eDelphi in a meaningful way.
eDelphi survey
The eDelphi questionnaire will be distributed using an on-
line e-management survey system, DelphiManager, main-
tained by the COMET Initiative. This system has
previously been successfully used in several studies to fa-
cilitate the determination of core outcome sets [18]. The
survey will be pilot tested among members of the TREAT
Research Group and AE patients, before going live.
The study will run over three online rounds (Fig. 1).
At the beginning of each round, the details of the study
with the key objective will be presented. Subsequently,
participants will be asked to rate each of the domains
and domain items using the GRADE (Grading of Rec-
ommendations Assessment, Development and Evalua-
tions) scale, a 9-point scale with 1 to 3 labelled ‘not
important’, 4 to 6 ‘important but not critical’ and 7 to 9
‘critical’ [19]. Participants will have the option of select-
ing ‘unable to score’ if they feel unable to rate and of
providing feedback on a specific item or in general at
the end of the survey. Hovering over the text will pro-
vide an explanation for key terms.
Table 1 List of (inter)national societies to be invited (Continued)
Society of Dermatologists, Venereologists
and Leprologists of Nepal (SODVELON)
Society of Dermatovenereology Turkey
(TURKDERM)
Society for Investigative Dermatology
USA (SID)
Spanish Academy of Dermatology and
Venereology (AEDV)
Sri Lanka College of Dermatologists
(SLCD)
Sudanese Association of Dermatology
Swedish Society for Dermatology and
Venereology (SSDV)
Swiss Society of Dermatology and
Venereology (SGDV/SSDV)
Syrian Arab Society of Dermatology
Taiwanese Dermatological Association
Tunisian Society of Dermatology and
Venereology
Turkish Society of Dermatology (TDD)
UK Translational Research Network in
Dermatology (UK TREND)
Uruguayan Dermatological Society (SDU)
Venezuelan Society of Dermatology and
Dermatologic Surgery (SVDCD)
Vietnamese Society of Dermatology and
Venereology (NIDV)
Allergy and contact
dermatitis societies
Dutch Society of Allergology (NVVA)
European Environmental and Contact
Dermatitis Research Group (EECDRG)
European Research Group on
Experimental Contact Dermatitis
(ERGECD)
European Society of Contact Dermatitis
(ESCD)
European Surveillance System on Contact
Allergies (ESSCA)
Irish Food Allergy Network (IFAN)
Table 2 List of eczema support (patient) societies to be invited
Name of society
Allergy New Zealand (NZ)
Association Française de l’Eczéma (FR)
Eczema – an Indian Perspective (IDA)
Eczema Association of Australasia (AU)
Eczema Association of Kenya (KE)
Eczema Outreach Scotland (UK, Scotland) Eczema Scotland (UK,
Scotland)
Irish Skin Foundation (IE)
Itchy Kids New Zealand (NZ)
La Prévention des Allergies (BE)
Malta Eczema Society (MT)
National Eczema Society (UK)
National Eczema Association (US)
South African National Eczema Association (SANEA) (ZA)
Swiss Allergy Centre (CH)
Talkhealth Partnership (UK)
The Eczema Society of Canada (CA)
Vereniging Mensen met Constitutioneel Eczeem (VMCE) (NL)
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Table 3 Proposed list of domains and domain items for round
1 of the eDelphi questionnaire
Domains Domain items
Demographics Social history
Marital history
Past AE treatments Previous topical treatments for AE
Previous day hospital care
treatments for AE
Previous hospitalisation for AE
Previous structured education
programme for AE
Current AE treatments Topical treatments
Allergy test results Delayed contact hypersensitivity
patch test
Atopy patch test
Double-blind, placebo-controlled
food challenge
Skin-prick testing to foods or
aeroallergens
Chronic (inflammatory)
comorbidities
Inflammatory bowel disease
Rheumatoid arthritis
Diabetes mellitus
Smoking/alcohol/recreational drug
history
Smoking history
Alcohol intake
Recreational drug history (soft
drugs)
Current concomitant medication
(i.e. other than specific AE
medication
Antihistamines, oral or topical
Topical antibiotics
Oral antibiotics
Allergic rhinoconjunctivitis
medication
Asthma medication
Baseline physical examination Fitzpatrick skin type
Weight and height for BMI
calculation
Blood pressure
Body temperature
Chest (lung) auscultation
Heart auscultation
Lymph node palpation (axillary and
inguinal)
Skin examination
Baseline physician and patient
reported domains
Physician-assessed clinical signs,
e.g. EASI or SCORAD score
Investigator/physician global
assessment, e.g. IGA
Patient-reported symptoms, e.g.
POEM, itch or sleep score
Patient global assessment, e.g. PGA
Generic quality of life score
Table 3 Proposed list of domains and domain items for round
1 of the eDelphi questionnaire (Continued)
Dermatology-specific quality of life
score
AE-specific quality of life score
Patient-reported satisfaction with
AE care received
Baseline investigations and
assessments
Blood testing for past/current
tuberculosis
Chest radiograph
Hepatitis B status
Hepatitis C status
Human immunodeficiency virus
(HIV) status
Varicella zoster virus (VZV) immune
status
Pregnancy
Monitoring P3NP in case of
methotrexate use in adults
Evaluating TPMT level prior to
azathioprine use
Collection of medical photographs
to monitor disease extent
Baseline biorepository samples Collection of blood for biomarkers,
e.g. TARC
Collection of DNA (blood or saliva)
for filaggrin analysis
Collection of biomaterials, e.g. DNA,
PBMC or skin biopsy, for a
biorepository
Baseline management Reasons for choosing specific
treatment (systemic or
phototherapy)
Routine recording of relative
contraindication(s) for selected
treatment
Follow-up general questions Minimum follow-up frequency for
registry data entry, once stable
therapeutic dose has been reached:
A. 2 months
B. 3 months
C. 4 months
D. 5 months
E. 6 months
Minimum follow-up frequency for
registry data entry, after stopping
photo- or systematic therapy:
A. 3 months
B. 6 months
C. Annually
D. No follow-up
Follow-up physical examination Weight and height for BMI
calculation
Blood pressure
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Table 3 Proposed list of domains and domain items for round
1 of the eDelphi questionnaire (Continued)
Body temperature
Chest (lung) auscultation
Heart auscultation
Lymph node palpation (axillary and
inguinal)
Skin examination
Follow-up physician- and patient-
reported domains
Physician-assessed clinical signs,
e.g. EASI or SCORAD score
Investigator/physician global
assessment, e.g. IGA
Patient-reported symptoms, e.g.
POEM, itch or sleep score
Patient global assessment, e.g. PGA
Generic quality of life score
Dermatology-specific quality of life
score
AE-specific quality of life score
Reporting of disease control, e.g.
flares, fully controlled weeks, by
physician
Reporting of disease control, e.g.
flares, fully controlled weeks, by
patient
Adherence to treatment between
appointments
Patient-reported satisfaction with
AE care received
Follow-up investigations and
assessments
Minimum frequency of safety
investigations:
A. 6 weeks
B. 8 weeks
C. 10 weeks
D. 12 weeks
E. 14 weeks
F. 16 weeks
Collection of medical photographs
to monitor disease extent
Follow-up biorepository samples Collection of blood for biomarkers,
e.g. TARC
Collection of biomaterials, e.g. DNA,
PBMC or skin biopsy, for a
biorepository
AE atopic eczema, BMI Body Mass Index, DNA deoxyribonucleic acid, EASI
Eczema Area and Severity Index, HIV Human Immunodeficiency Virus, IGA
Investigator Global Assessment, P3NP procollagen type III N-terminal peptide,
PBMC peripheral blood mononuclear cell, PGA Patient Global Assessment,
POEM Patient-oriented Eczema Measure, SCORAD SCORing Atopic Dermatitis
Index, TARC thymus and activation-regulated chemokine, VZV varicella
zoster virus
Table 4 List of obvious domains and domain items
Domains Domain items
Related to baseline
‘demographics and AE’
Demographics Date of birth and date of
enrolment into registry
Gender
Ethnicity
Educational status
Current occupation or education
AE diagnosis How diagnosis AE is established
Use of validated diagnostic criteria
Date of onset AE
Past AE treatments Previous phototherapy
Previous systemic therapy
Current AE treatments Phototherapy
Systemic immunosuppressive
therapy
Family history of AE or
allergic diseases
Related to baseline
‘past medical relevant history’
Allergic comorbidities Asthma
Allergic rhinoconjunctivitis
Atopic eye disease
Eosinophilic oesophagitis
Food allergies
Contact allergies
Other comorbidities Past malignancies
Past serious infections
Related to baseline
‘investigations and assessments’
Baseline safety investigations Medical history (tuberculosis)
Full blood count
Liver function
Kidney profile
Related to follow-up visits
Follow up ‘adverse drug
reactions’
Serious adverse events
Adverse events that cause
stop or switch of therapy or
change in dosage
For (serious) adverse events:
probability of relationship with
treatment
Follow-up ‘management’
Reason for switching therapy
Reason for discontinuation of therapy
AE atopic eczema
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Participants will be asked to complete each round of
the eDelphi exercise and reminder emails will be sent
to increase the response rate. To reduce the risk of at-
trition bias, the importance of completing all eDelphi
rounds will be highlighted to all participants at the out-
set of each round. Participants who save an incomplete
questionnaire will be contacted to encourage comple-
tion. Furthermore, we will provide clear timelines for
the completion of each round and send out personal re-
minder emails.
eDelphi round 1
Round-1 content includes (1) demographic data of
the participants (age, gender, country of practice, the
participants’ stakeholder group, current position (in
case of health care professionals), age group of AE
patients they predominantly care for (in case of
health care professionals), how much experience they
have in the care of AE patients (in case of health care
professionals), membership of an international derma-
tology society or AE interest group), (2) the obvious
list of domains and their items to be reviewed and
potentially commented on, (3) a list of domains with
their items to be scored and (4) an option to add any
additional domains or domain items.
The total number of registered participants for round
1 will be recorded as the number of participants who
have actually completed the rating of the domains and
domain items.
eDelphi round 2
All domains and domain items will be carried through
to the second round. Additional domains and items
listed by participants will be reviewed by the TREAT Re-
search Group and included in round 2.
In this second round, each participant will be asked to
rate the domains and domain items again, together with
any additional domains and domain items from round 1.
They will be presented with the number of participants
who scored and the distribution of scores (%) for each
domain and domain item for their particular stakeholder
group with a reminder of their own round 1 score. They
will be asked to consider responses from the other mem-
bers of their stakeholder group before rescoring each do-
main and domain item.
Reasons for changes to scores will be documented by
asking participants at the end of round 2 to give a gen-
eral view of why they changed scores.
Those who have not participated in, or completed,
the first round will not be invited to round 2. The
total number of invited participants for round 2 will
be recorded as the number of participants who have
actually completed the rating of the domains and
domain items. All domains and domain items will be
carried forward to round 3.
eDelphi round 3
An overview of the domains and domain items that have
reached consensus will be presented at the beginning of
the round-3 survey.
In this third round, all participants will receive identi-
cal feedback, containing the distribution of scores (%)
for each domain and each domain item for all stake-
holder groups, along with a reminder of their round 2
score. They will then be asked to rescore.
All participants included in round 2 will be invited
for round 3. As with the previous rounds, the total
number of invited participants for round 3 will be
recorded as the number of participants who have ac-
tually completed the rating of the domains and
items. Results of each stakeholder group will be de-
termined. This will lead to the classification of each
domain or domain item as ‘consensus in’, ‘consensus
out’ or ‘no consensus’ for each stakeholder group
separately, which will be used in the final consensus
meeting.
Consensus meeting
All eDelphi participants will be asked in round 3 of the
survey if they are willing to attend the consensus meet-
ing. The meeting will be held face-to-face at a location
agreed by the TREAT Research Group and/or by tele-
phone conference within 4 months after the close of
round 3. The consensus meeting will be attended by rep-
resentatives of all eDelphi stakeholder groups. All those
who completed the three rounds are eligible. Represen-
tation of health care professionals and patients will be of
particular importance.
One non-voting neutral participant will act as a facili-
tator and ensure that the voices of all representative
groups are heard, and that the process is not dominated
by individual participants.
The nominal group technique will be used [15, 20]. The
facilitator will present the results of each round of the
eDelphi as a summary of response rates, attrition rates,
change in scores in case no consensus is reached and do-
mains or domain items that have reached consensus. The
meeting will be held to ratify the domains and/or domain
items for which consensus are reached and discuss those
where ‘no consensus’ is reached or where there is signifi-
cant disagreement about importance between stakeholder
groups. Consensus results from the eDelphi can only be
overturned in this meeting if reasons are very strong and
transparent, the same applies for opening discussion
around new domains or domain items.
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For the domains and domain items that have not
reached consensus, voting will take place, ideally anon-
ymised by using electronic handsets and TurningPoint©
software to analyse the results in real time.
Definition of consensus and core set
The definition of consensus for the eDelphi exercise is
based on that proposed by the Management of Otitis
Media with Effusion in Children with Cleft Palate (MO-
MENT) study group [21], but amended to take into consid-
eration the multiple stakeholder groups. This definition
ensures that the vast majority considers an item to be crit-
ically important in the absence of a sizeable minority think-
ing the opposite. Consensus that a domain or domain item
should be included in the core set will be referred to as
‘consensus in’. It will be defined as 70% or more of partici-
pants in each stakeholder group scoring its importance as 7
to 9 and less than 15% scoring it as 1 to 3. For ‘consensus
out’ it is the other way around, i.e. 70% or more participants
scoring as 1 to 3 and less than 15% scoring as 7 to 9. If
there is uncertainty about the importance, it will be referred
to as ‘no consensus’. Any item where all stakeholder groups
confirm ‘consensus in’ will be taken to be in the core out-
come set.
The definition of consensus for the consensus meeting
is applied as used by the Outcome Measures in Rheuma-
tology Collaboration (OMERACT) group and the
HOME initiative [22–24]. Consensus that a domain or
domain item should be included in the core set will be
defined as less than 30% of the whole group of partici-
pants disagrees, i.e. not scoring 7 to 9 (one-sided con-
sensus rule). Instead of using the eDelphi consensus rule
for each stakeholder group separately, we will apply this
different rule to avoid a small stakeholder group decid-
ing ‘consensus out’ when the rest of the stakeholder
groups decide ‘consensus in’.
A core set is defined as a list of variables that are es-
sential to collect for any patient/subject [12].
Analysis of results
The results of the third and final eDelphi round will be
analysed separately for each stakeholder group using the
abovementioned definition of ‘consensus in’ and ‘consen-
sus out’. The consensus meeting results will be evaluated
for the whole group using the ‘one-sided consensus rule’.
Data management
Confidentiality of the survey data will be ensured by the
use of unique numerical identifiers, anonymously allocated
to participants, to ensure unrecognizability of individual re-
sponses. Data will be password-protected and accessible
only to the TREAT Research Group, whose members will
under no circumstances breach confidentiality.
Ethical requirements
Consent to participate will be assumed if individuals agree
to participate and complete the online questionnaires.
Ethical guidance has been obtained from the Medical
Ethics Review Committee of the Academic Medical Center
in Amsterdam (reference number W15_249 # 15.0294).
The committee confirmed that the Medical Research In-
volving Human Subjects Act (WMO) does not apply to this
study and that no official approval is required.
Discussion
By the end of this Delphi study we hope to have reached
consensus on the core set of domains and domain items
to capture in AE patient registries with a research focus,
that collect data of children and adults on photo- and sys-
temic immunomodulatory therapies. This internationally
agreed core set has the potential to unify data collection
within existing and future AE patient registries to allow
direct comparisons and data sharing and pooling. Analysis
of these registry data will facilitate insight into the effect-
iveness, safety and cost-effectiveness of photo- and sys-
temic immunomodulatory therapies across dermatology
centres and country boundaries.
Applying the Delphi method has several advantages.
First, it allows us to include a large group of international
experts and patients who are geographically dispersed to
participate. In this way, broad consensus can be obtained.
Second, the anonymity of the survey may avoid the dom-
inance of certain persons in contrast to face-to-face meet-
ings. However, this could diminish the positive effects of
interaction to be found in face-to-face meetings, which
helps to identify reasons for disagreement [17]. Therefore,
a final consensus meeting will be held in case of remaining
disagreements. Third, feedback is given to participants,
allowing them to consider the answers of not only their
own but also of other stakeholder groups.
Despite the obvious advantages of the eDelphi process,
there are several sources of possible biases. Specifically,
there is a risk of disproportionate representation among
individual groups, including a dominance of clinicians
and researchers, and relative underrepresentation of
other groups such as patients and families [14]. By con-
tacting patient organisations and using personal con-
tacts, we hope to enrol sufficient numbers within this
important stakeholder group. Dominance of individual
participants or representatives of one specific stake-
holder group at the face-to-face consensus meeting may
be another risk. The deployment of an independent fa-
cilitator will minimise this risk by ensuring that all
voices will be adequately heard. Furthermore, we have
chosen to use a prespecified list of domains and domain
items in the survey next to an obvious list suggested by
our research group. This may bias responses of partici-
pants and overstate the importance of domains and
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domain items recognised by our research group [25].
However, this was done in an effort to optimise the effi-
ciency and feasibility of the survey. Additionally, partici-
pants will have the opportunity to add domains and
domain items and to comment on the obvious list in the
first round. Another consideration is that patients may
struggle to interpret the medical terminology used in the
eDelphi, which in turn may limit the value of their re-
sponse. We will, therefore, involve patient organisations
and patients in the development and pilot phase, include
help texts in the survey and use plain English where pos-
sible. A further potential problem is a declining response
rate from round to round [17]. Reminder emails will en-
courage completion of questionnaires, and we will also
only invite people who responded to a pre-Delphi invita-
tion, as they are likely to be more motivated to complete
the survey. In addition, the extent of the core set may be
a hurdle for patients as they may struggle to tell the dif-
ference between what is important to themselves and
what is important to be included in a patient registry
that is focussed on research. This may encourage them
to include more domains and/or domain items than
other stakeholder groups or to dismiss domains and/or
domain items that they see as unimportant, e.g. surveil-
lance data. This may impact the feasibility of the final
core set. Therefore, we will highlight the importance of
agreeing on a core set in each round of the eDelphi sur-
vey and at the consensus meeting. Another point of de-
bate is the challenge to accommodate potential cross-
cultural differences in a core set. We will, therefore, ex-
tend our invitation to take part in the eDelphi exercise
to colleagues in (East) Asia, Africa, South America, and
Australia and New Zealand, in addition to European
and North American participant representation (see
Tables 1 and 2 with dermatology societies and eczema pa-
tient support groups to be invited). Lastly, a core set will
only have impact if it is consistently implemented in pa-
tient registries with a research focus. To achieve imple-
mentation in these registries, we must actively engage
with all stakeholders, especially international societies and
regulatory bodies after the Delphi exercise is completed to
ensure that this core set is accepted and used.
Study status
The eDelphi study is currently ongoing. After the data of the
eDelphi are analysed, a consensus meeting will be planned
for defining the final core set of domains and domain items.
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